Yayın:
Pooled prevalence and trends of antimicrobial resistance in Pseudomonas aeruginosa clinical isolates over the past 10 years in Turkey: A meta-analysis

dc.contributor.authorAcar, Ali
dc.contributor.authorKaraahmetoglu, Gökhan
dc.contributor.authorAltay, Aybala F.
dc.contributor.buuauthorAkalın, Halis
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentDahili Tıp Bilimleri
dc.contributor.departmentEnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı
dc.contributor.researcheridAAU-8952-2020
dc.contributor.scopusid57207553671
dc.date.accessioned2023-04-14T12:08:33Z
dc.date.available2023-04-14T12:08:33Z
dc.date.issued2019-09
dc.description.abstractObjectives: This meta-analysis aimed to evaluate the current prevalence and trends over the past 10 years of Pseudomonas aeruginosa (P. aeruginosa) antimicrobial resistance. Two researches independently searched two national (ULAKBIM, Turk Medline) and two international databases (PubMed, Web of Science) to identify studies on P. aeruginosa resistance to antimicrobials from 2007 to 2017. Methods: Homogeneity across studies was assessed using Cochrane guidelines, and total variability due to between-study variations was reflected in the I-2 index. A random effects model was developed to estimate the antimicrobial resistance rates and their corresponding 95% CI. Pooled antibiotic resistance rates between 2007-2011 and 2012-2016 were compared to calculate the change in antibiotic resistance over time. Electronic searches with MeSH terms and text words identified 1017 papers. After applying exclusion and inclusion criteria, 45 articles were selected. Results: Pooled resistance prevalence of P. aeruginosa to piperacillin-tazobactam, ceftazidime, cefepime, meropenem, imipenem, ciprofloxacin, gentamicin, amikacin, tobramycin and colistin were 33.9%, 38.6%, 35.6%, 30.1%, 28.0%, 30.7%, 28.2%, 17.8%, 15.7% and 2.2%, respectively. The resistance rates of piperacillin, piperacillin-tazobactam, imipenem, meropenem, amikacin and colistin significantly increased in the second 5 years (P < 0.05); however, gentamicin, tobramycin and ciprofloxacin resistance rates significantly decreased (P < 0.05). Comparing the resistance rates between the isolates of intensive care unit (ICU) patients and non-ICU patients, meropenem and piperacillin-tazobactam resistance in ICU isolates were significantly higher than non-ICU (P < 0.05). Conclusions: These results suggest that antibiotic resistance is high in P. aeruginosa and the trends in antimicrobial resistance continue to increase, mainly in carbapenems and penicillins, in Turkey.
dc.identifier.citationAcar, A . vd. (2019). ''Pooled prevalence and trends of antimicrobial resistance in Pseudomonas aeruginosa clinical isolates over the past 10 years in Turkey: A meta-analysis''. Journal of Global Antimicrobial Resistance, 18, 64-70.
dc.identifier.doi10.1016/j.jgar.2019.01.032
dc.identifier.endpage70
dc.identifier.issn2213-7165
dc.identifier.issn2213-7173
dc.identifier.pubmed30753904
dc.identifier.scopus2-s2.0-85067596841
dc.identifier.startpage64
dc.identifier.urihttps://doi.org/10.1016/j.jgar.2019.01.032
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S2213716519300396
dc.identifier.urihttp://hdl.handle.net/11452/32398
dc.identifier.volume18
dc.identifier.wos000485661700013
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherElsevier
dc.relation.collaborationYurt içi
dc.relation.journalJournal of Global Antimicrobial Resistance
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectInfectious diseases
dc.subjectPharmacology & pharmacy
dc.subjectPseudomonas aeruginosa
dc.subjectAntibiotic resistance
dc.subjectMeta-analysis
dc.subjectTurkey
dc.subjectRisk-Factors
dc.subjectTurkish Hospitals
dc.subjectSurveililance
dc.subjectConsumption
dc.subjectInfections
dc.subject.emtreeAmikacin
dc.subject.emtreeAntibiotic agent
dc.subject.emtreeAztreonam
dc.subject.emtreeCefepime
dc.subject.emtreeCefoperazone plus sulbactam
dc.subject.emtreeCeftazidime
dc.subject.emtreeCiprofloxacin
dc.subject.emtreeColistin
dc.subject.emtreeGentamicin
dc.subject.emtreeImipenem
dc.subject.emtreeLevofloxacin
dc.subject.emtreeMeropenem
dc.subject.emtreeNetilmicin
dc.subject.emtreePiperacillin plus tazobactam
dc.subject.emtreeTobramycin
dc.subject.emtreeAntiinfective agent
dc.subject.emtreeAntibiotic resistance
dc.subject.emtreeArticle
dc.subject.emtreeBacterium isolate
dc.subject.emtreeCritically ill patient
dc.subject.emtreeEvaluation study
dc.subject.emtreeHuman
dc.subject.emtreeIntensive care unit
dc.subject.emtreeMedical Subject Headings
dc.subject.emtreeMedline
dc.subject.emtreeNonhuman
dc.subject.emtreePrevalence
dc.subject.emtreePriority journal
dc.subject.emtreePseudomonas aeruginosa
dc.subject.emtreeSystematic review
dc.subject.emtreeTrend study
dc.subject.emtreeTurkey (republic)
dc.subject.emtreeWeb of Science
dc.subject.emtreeDrug effect
dc.subject.emtreeMeta analysis
dc.subject.emtreeMicrobial sensitivity test
dc.subject.emtreeMicrobiology
dc.subject.emtreeMultidrug resistance
dc.subject.emtreePseudomonas aeruginosa
dc.subject.emtreePseudomonas infection
dc.subject.emtreeTurkey (bird)
dc.subject.meshAnti-Bacterial Agents
dc.subject.meshDrug Resistance, Multiple, Bacterial
dc.subject.meshHumans
dc.subject.meshIntensive Care Units
dc.subject.meshMicrobial Sensitivity Tests
dc.subject.meshPrevalence
dc.subject.meshPseudomonas aeruginosa
dc.subject.meshPseudomonas Infections
dc.subject.meshTurkey
dc.subject.scopusCarbapenems; Microbial Sensitivity Tests; Pseudomonas Aeruginosa
dc.subject.wosInfectious Diseases
dc.subject.wosPharmacology & pharmacy
dc.titlePooled prevalence and trends of antimicrobial resistance in Pseudomonas aeruginosa clinical isolates over the past 10 years in Turkey: A meta-analysis
dc.typeArticle
dc.wos.quartileQ3 (Infectious diseases)
dc.wos.quartileQ2 (Pharmacology & pharmacy)
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Dahili Tıp Bilimleri/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı
local.indexed.atPubMed
local.indexed.atWOS

Dosyalar

Lisanslı seri

Şimdi gösteriliyor 1 - 1 / 1
Placeholder
Ad:
license.txt
Boyut:
1.71 KB
Format:
Item-specific license agreed upon to submission
Açıklama